Subclinical Peripheral Neuropathy in Patients With Multiple Myeloma Before Chemotherapy Is Correlated With Decreased Fingertip Innervation Density.
Kosturakis AK et al. J Clin Oncol. 2014 Aug 25. pii: JCO.2013.54.5418. [Epub ahead of print].
Hepatitis B virus reactivation in multiple myeloma patients receiving bortezomib-containing regimens followed by autologous stem cell transplantation.
Li J et al. Leuk Lymphoma. 2014 Aug 7:1-27. [Epub ahead of print].
Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients.
Koh Y et al. Cancer Chemother Pharmacol. 2014 Aug 6. [Epub ahead of print].
Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure.
Breitkreutz I et al. Bone Marrow Transplant. 2014 Aug 4. doi: 10.1038/bmt.2014.165. [Epub ahead of print].
Peripheral neuropathy exacerbated by lenalidomide in a patient with multiple myeloma.
Kamimura T et al. Intern Med. 2014;53(15):1651-3. Epub 2014 Aug 1.
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma.
Brioli A et al. Haematologica. 2014 Aug 1. pii: haematol.2014.110221. [Epub ahead of print].
Renal Insufficiency in Newly-diagnosed Multiple Myeloma: Analysis According to International Myeloma Working Group Consensus Statement.
Park S et al. Anticancer Res. 2014 Aug;34(8):4299-306.